- Home
- GXAI vs KZIA Comparison
GXAI vs KZIA Comparison
Compare GXAI & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | KZIA |
|---|---|---|
| Founded | 2021 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 93.2M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | GXAI | KZIA |
|---|---|---|
| Price | $1.36 | $8.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | ★ 11.4M | 189.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,027.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1473.05 | N/A |
| 52 Week Low | $1.00 | $0.64 |
| 52 Week High | $2.96 | $17.40 |
Technical Indicators
Market Signals| Indicator | GXAI | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 54.50 |
| Support Level | $1.11 | $5.74 |
| Resistance Level | $1.38 | $8.17 |
| Average True Range (ATR) | 0.16 | 1.11 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 22.99 | 32.21 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.